Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

摘要: Topoisomerase II is a key target for several anti-cancer drugs used breast cancer therapy, including doxorubicin, epirubicin and mitoxantrone. Two isoforms of topoisomerase (alpha beta) have been described in human cells which differ their subcellular localisation, biochemical properties susceptibility to inhibition by drugs. The relative level expression the alpha beta may contribute degree tumour responsiveness different chemotherapeutic agents. To assess relationship between established prognostic factors pathological variables, 56 primary samples were studied. two genes was apparently not co-ordinately regulated these tissue samples. There no any commonly variables [tumour size, lymph node status, S-phase fraction (SPF)] mRNA. However, high gene significantly associated with SPF (sign-rank test; P = 0.01). Moreover, ratio mRNA levels showed stronger (median raito 0.62 tumours 10; 0.0021, sign-rank test). As expected from previous studies, an > 10 poor overall survival (P Immunohistochemical analysis revealed that widely distributed ( 90% positive cells), but less expressed, pattern similar proliferation-dependent antigen recognised Ki67. Because log-normal distribution, log-transformed data multivariate relapse-free survival. This status only significant 0.001 0.05, respectively, risks 1.3 1.8). These results indicate alpha, beta, dependent upon cellular proliferation more expressed protein play role as anti-tumour therapy.